Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hydatidiform Mole | 27 | 2023 | 279 | 6.890 |
Why?
|
Uterine Neoplasms | 24 | 2024 | 1511 | 3.170 |
Why?
|
Genital Neoplasms, Female | 7 | 2023 | 513 | 3.050 |
Why?
|
Ovarian Neoplasms | 25 | 2023 | 4815 | 2.910 |
Why?
|
Choriocarcinoma | 7 | 2024 | 123 | 1.510 |
Why?
|
Methotrexate | 15 | 2023 | 1711 | 1.480 |
Why?
|
MicroRNAs | 7 | 2023 | 3712 | 1.300 |
Why?
|
Chorionic Gonadotropin | 18 | 2024 | 475 | 1.250 |
Why?
|
Neoplasms, Glandular and Epithelial | 4 | 2016 | 485 | 1.180 |
Why?
|
Pregnancy | 62 | 2024 | 29002 | 1.010 |
Why?
|
Perioperative Care | 6 | 2023 | 995 | 1.010 |
Why?
|
Early Detection of Cancer | 3 | 2023 | 3051 | 0.890 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2023 | 114 | 0.870 |
Why?
|
Gynecologic Surgical Procedures | 7 | 2023 | 335 | 0.870 |
Why?
|
Dactinomycin | 8 | 2023 | 317 | 0.810 |
Why?
|
Vacuum Curettage | 5 | 2021 | 48 | 0.790 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 11410 | 0.770 |
Why?
|
Iodide Peroxidase | 1 | 2021 | 293 | 0.700 |
Why?
|
Female | 112 | 2024 | 378853 | 0.660 |
Why?
|
Salpingectomy | 1 | 2018 | 52 | 0.640 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 221 | 0.620 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2020 | 640 | 0.620 |
Why?
|
Cervix Uteri | 2 | 2021 | 591 | 0.620 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 704 | 0.610 |
Why?
|
Drug Resistance, Neoplasm | 9 | 2023 | 5148 | 0.600 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2021 | 2012 | 0.590 |
Why?
|
Brazil | 17 | 2023 | 1264 | 0.570 |
Why?
|
Serum | 1 | 2017 | 211 | 0.560 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2021 | 1213 | 0.560 |
Why?
|
Endometrial Neoplasms | 2 | 2023 | 1351 | 0.550 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 199 | 0.550 |
Why?
|
Ovariectomy | 1 | 2018 | 660 | 0.530 |
Why?
|
Research Report | 1 | 2019 | 351 | 0.530 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2018 | 323 | 0.520 |
Why?
|
Antineoplastic Agents | 9 | 2023 | 13635 | 0.510 |
Why?
|
Disease Progression | 3 | 2021 | 13237 | 0.500 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2024 | 9122 | 0.500 |
Why?
|
Germ Cells | 1 | 2018 | 627 | 0.490 |
Why?
|
Critical Illness | 3 | 2017 | 2656 | 0.480 |
Why?
|
Dilatation and Curettage | 2 | 2012 | 56 | 0.480 |
Why?
|
Humans | 115 | 2024 | 739398 | 0.460 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1431 | 0.460 |
Why?
|
Hysterectomy | 4 | 2020 | 926 | 0.460 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 480 | 0.450 |
Why?
|
Interferon Type I | 1 | 2017 | 541 | 0.450 |
Why?
|
Etoposide | 4 | 2023 | 637 | 0.430 |
Why?
|
DNA Methylation | 2 | 2023 | 4269 | 0.420 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2023 | 1702 | 0.420 |
Why?
|
Papillomavirus Infections | 2 | 2021 | 1585 | 0.410 |
Why?
|
Checklist | 1 | 2019 | 817 | 0.400 |
Why?
|
Cystadenocarcinoma, Serous | 3 | 2022 | 449 | 0.390 |
Why?
|
Appendectomy | 1 | 2013 | 398 | 0.380 |
Why?
|
Vincristine | 3 | 2023 | 1038 | 0.380 |
Why?
|
Cohort Studies | 26 | 2024 | 40389 | 0.370 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2022 | 221 | 0.370 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 1380 | 0.370 |
Why?
|
Cell Lineage | 2 | 2018 | 2486 | 0.360 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2013 | 499 | 0.360 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1143 | 0.350 |
Why?
|
CA-125 Antigen | 2 | 2022 | 278 | 0.350 |
Why?
|
Neoplasm Staging | 14 | 2021 | 10961 | 0.340 |
Why?
|
Placenta | 5 | 2024 | 1682 | 0.330 |
Why?
|
Telemedicine | 2 | 2023 | 2844 | 0.330 |
Why?
|
Anesthetics | 1 | 2014 | 536 | 0.330 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1673 | 0.330 |
Why?
|
Retrospective Studies | 36 | 2023 | 76631 | 0.320 |
Why?
|
Leucovorin | 5 | 2021 | 618 | 0.310 |
Why?
|
BRCA2 Protein | 2 | 2023 | 788 | 0.310 |
Why?
|
Adult | 47 | 2023 | 213394 | 0.300 |
Why?
|
Interleukin-17 | 3 | 2008 | 894 | 0.300 |
Why?
|
Killer Cells, Natural | 4 | 2022 | 2133 | 0.270 |
Why?
|
Patient Care Team | 1 | 2017 | 2527 | 0.270 |
Why?
|
T-Lymphocytes, Helper-Inducer | 2 | 2008 | 986 | 0.260 |
Why?
|
Gene Expression Profiling | 7 | 2022 | 9387 | 0.250 |
Why?
|
Middle Aged | 35 | 2021 | 212863 | 0.250 |
Why?
|
Tretinoin | 1 | 2007 | 513 | 0.250 |
Why?
|
Trophoblasts | 2 | 2016 | 214 | 0.240 |
Why?
|
Research Design | 2 | 2022 | 5959 | 0.240 |
Why?
|
Postoperative Complications | 3 | 2023 | 15194 | 0.220 |
Why?
|
Alkylating Agents | 1 | 2023 | 138 | 0.220 |
Why?
|
Watchful Waiting | 2 | 2017 | 489 | 0.220 |
Why?
|
Sensitivity and Specificity | 4 | 2023 | 14740 | 0.210 |
Why?
|
Hyperthyroidism | 2 | 2022 | 293 | 0.210 |
Why?
|
Young Adult | 21 | 2021 | 56255 | 0.200 |
Why?
|
Endometriosis | 2 | 2022 | 832 | 0.200 |
Why?
|
Decidua | 1 | 2022 | 86 | 0.200 |
Why?
|
Least-Squares Analysis | 1 | 2022 | 382 | 0.200 |
Why?
|
Length of Stay | 4 | 2023 | 6295 | 0.200 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7274 | 0.190 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5213 | 0.190 |
Why?
|
Growth Differentiation Factor 2 | 1 | 2020 | 25 | 0.190 |
Why?
|
Uterine Artery | 1 | 2020 | 36 | 0.190 |
Why?
|
Colposcopy | 1 | 2021 | 144 | 0.180 |
Why?
|
Forkhead Transcription Factors | 1 | 2007 | 1602 | 0.180 |
Why?
|
Mitoxantrone | 1 | 2020 | 148 | 0.180 |
Why?
|
Ascites | 1 | 2022 | 342 | 0.180 |
Why?
|
Risk Factors | 17 | 2023 | 71974 | 0.170 |
Why?
|
Selenoproteins | 1 | 2021 | 216 | 0.170 |
Why?
|
Cyclophosphamide | 3 | 2023 | 2238 | 0.170 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2022 | 322 | 0.170 |
Why?
|
Adenocarcinoma | 4 | 2019 | 6318 | 0.170 |
Why?
|
Fallopian Tubes | 1 | 2019 | 182 | 0.170 |
Why?
|
Fertility | 1 | 2023 | 775 | 0.160 |
Why?
|
Cytarabine | 1 | 2020 | 685 | 0.160 |
Why?
|
Doxycycline | 1 | 2019 | 327 | 0.160 |
Why?
|
Aged | 17 | 2021 | 162698 | 0.150 |
Why?
|
Remission Induction | 2 | 2020 | 2378 | 0.150 |
Why?
|
Adolescent | 16 | 2021 | 85405 | 0.150 |
Why?
|
Smoke Inhalation Injury | 1 | 2017 | 49 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2021 | 8400 | 0.150 |
Why?
|
Blood Loss, Surgical | 1 | 2021 | 658 | 0.150 |
Why?
|
Hypothyroidism | 1 | 2022 | 659 | 0.140 |
Why?
|
Cysts | 1 | 2022 | 674 | 0.140 |
Why?
|
Drug Substitution | 1 | 2019 | 283 | 0.140 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2017 | 187 | 0.140 |
Why?
|
Fallopian Tube Diseases | 1 | 2016 | 62 | 0.140 |
Why?
|
Ovarian Diseases | 1 | 2017 | 139 | 0.130 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3571 | 0.130 |
Why?
|
Remote Consultation | 1 | 2018 | 239 | 0.130 |
Why?
|
Demography | 1 | 2020 | 1650 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3453 | 0.130 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 1820 | 0.130 |
Why?
|
Morphogenesis | 1 | 2018 | 759 | 0.130 |
Why?
|
Uterine Hemorrhage | 2 | 2017 | 255 | 0.120 |
Why?
|
GATA3 Transcription Factor | 1 | 2015 | 157 | 0.120 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2017 | 255 | 0.120 |
Why?
|
HeLa Cells | 1 | 2021 | 3119 | 0.120 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2022 | 3922 | 0.120 |
Why?
|
Organoplatinum Compounds | 1 | 2016 | 409 | 0.120 |
Why?
|
Elafin | 1 | 2014 | 33 | 0.120 |
Why?
|
Models, Statistical | 2 | 2022 | 5113 | 0.120 |
Why?
|
Genetic Markers | 1 | 2020 | 2630 | 0.120 |
Why?
|
Triage | 1 | 2021 | 975 | 0.120 |
Why?
|
Mutation | 6 | 2023 | 29658 | 0.120 |
Why?
|
Prognosis | 6 | 2022 | 28901 | 0.120 |
Why?
|
Pregnancy Outcome | 2 | 2021 | 2789 | 0.120 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2017 | 599 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3863 | 0.120 |
Why?
|
Doxorubicin | 1 | 2020 | 2218 | 0.120 |
Why?
|
Data Mining | 1 | 2018 | 536 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2021 | 5058 | 0.110 |
Why?
|
Logistic Models | 6 | 2019 | 13402 | 0.110 |
Why?
|
STAT3 Transcription Factor | 2 | 2007 | 875 | 0.110 |
Why?
|
Polysaccharides | 1 | 2020 | 1050 | 0.110 |
Why?
|
Multivariate Analysis | 4 | 2020 | 12237 | 0.110 |
Why?
|
Aged, 80 and over | 9 | 2021 | 57650 | 0.110 |
Why?
|
Treatment Outcome | 9 | 2022 | 62693 | 0.110 |
Why?
|
Cell Line, Tumor | 4 | 2017 | 16646 | 0.110 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2017 | 483 | 0.110 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2017 | 699 | 0.110 |
Why?
|
Multiple Organ Failure | 1 | 2015 | 385 | 0.110 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 4014 | 0.110 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3508 | 0.110 |
Why?
|
DNA, Viral | 1 | 2019 | 2223 | 0.100 |
Why?
|
Prospective Studies | 6 | 2023 | 53037 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1754 | 0.100 |
Why?
|
Immunohistochemistry | 6 | 2016 | 11347 | 0.100 |
Why?
|
Risk Reduction Behavior | 1 | 2018 | 1123 | 0.100 |
Why?
|
Databases, Genetic | 1 | 2018 | 1777 | 0.100 |
Why?
|
Prenatal Diagnosis | 1 | 2018 | 1227 | 0.100 |
Why?
|
Brachytherapy | 1 | 2019 | 1247 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2017 | 1453 | 0.100 |
Why?
|
Tissue Inhibitor of Metalloproteinases | 1 | 2011 | 99 | 0.100 |
Why?
|
Abortion, Induced | 1 | 2017 | 441 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2020 | 1357 | 0.100 |
Why?
|
Mice | 8 | 2023 | 81002 | 0.100 |
Why?
|
Follow-Up Studies | 5 | 2020 | 38942 | 0.090 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 1994 | 0.090 |
Why?
|
Gynecology | 1 | 2016 | 508 | 0.090 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2688 | 0.090 |
Why?
|
Neutrophils | 1 | 2022 | 3698 | 0.090 |
Why?
|
Receptors, Retinoic Acid | 2 | 2007 | 232 | 0.090 |
Why?
|
Health Care Costs | 1 | 2023 | 3226 | 0.090 |
Why?
|
Recovery of Function | 2 | 2017 | 2924 | 0.090 |
Why?
|
Mice, SCID | 1 | 2015 | 2716 | 0.090 |
Why?
|
Consensus | 1 | 2019 | 2913 | 0.090 |
Why?
|
Animals | 10 | 2023 | 168368 | 0.090 |
Why?
|
Estradiol | 1 | 2017 | 2021 | 0.090 |
Why?
|
Carcinosarcoma | 1 | 2010 | 108 | 0.090 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 188 | 0.080 |
Why?
|
Obstetrics | 1 | 2016 | 660 | 0.080 |
Why?
|
Mice, Nude | 1 | 2015 | 3692 | 0.080 |
Why?
|
Matrix Metalloproteinases | 1 | 2011 | 391 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1435 | 0.080 |
Why?
|
South America | 2 | 2020 | 181 | 0.080 |
Why?
|
Guideline Adherence | 1 | 2019 | 2261 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2141 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2021 | 3514 | 0.080 |
Why?
|
Mass Screening | 1 | 2023 | 5265 | 0.080 |
Why?
|
Immunotherapy | 2 | 2023 | 4391 | 0.080 |
Why?
|
Gestational Age | 2 | 2021 | 3486 | 0.080 |
Why?
|
Survival Rate | 3 | 2020 | 12761 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2017 | 2933 | 0.070 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2018 | 3615 | 0.070 |
Why?
|
STAT5 Transcription Factor | 1 | 2007 | 262 | 0.070 |
Why?
|
Survivors | 1 | 2017 | 2280 | 0.070 |
Why?
|
Cell Dedifferentiation | 1 | 2007 | 134 | 0.070 |
Why?
|
Prevalence | 1 | 2023 | 15153 | 0.070 |
Why?
|
Computational Biology | 1 | 2018 | 3506 | 0.070 |
Why?
|
Hong Kong | 2 | 2017 | 148 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5128 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2010 | 774 | 0.070 |
Why?
|
Burns | 1 | 2017 | 1808 | 0.070 |
Why?
|
Forecasting | 1 | 2015 | 2952 | 0.070 |
Why?
|
Disease-Free Survival | 4 | 2020 | 6871 | 0.070 |
Why?
|
Mortality | 1 | 2017 | 2851 | 0.070 |
Why?
|
Critical Care | 2 | 2016 | 2624 | 0.070 |
Why?
|
Blood Glucose | 1 | 2020 | 6237 | 0.070 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 888 | 0.070 |
Why?
|
Genes, Dominant | 1 | 2008 | 883 | 0.060 |
Why?
|
Insulin | 1 | 2020 | 6569 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2022 | 7862 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3021 | 0.060 |
Why?
|
Algorithms | 2 | 2022 | 13872 | 0.060 |
Why?
|
Risk | 3 | 2022 | 9684 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2017 | 15036 | 0.060 |
Why?
|
Abortion, Spontaneous | 2 | 2021 | 526 | 0.060 |
Why?
|
Signal Transduction | 1 | 2007 | 23355 | 0.060 |
Why?
|
Apoptosis | 2 | 2020 | 9714 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3138 | 0.060 |
Why?
|
Interleukin-2 | 2 | 2008 | 1883 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2394 | 0.060 |
Why?
|
Developing Countries | 1 | 2016 | 2779 | 0.060 |
Why?
|
Delirium | 1 | 2015 | 1604 | 0.060 |
Why?
|
Cross-Sectional Studies | 5 | 2023 | 24714 | 0.060 |
Why?
|
Cellular Structures | 1 | 2022 | 11 | 0.060 |
Why?
|
Incidence | 1 | 2021 | 20913 | 0.050 |
Why?
|
Interleukins | 1 | 2007 | 788 | 0.050 |
Why?
|
Cell Line | 1 | 2017 | 15987 | 0.050 |
Why?
|
Proteomics | 3 | 2022 | 3584 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4935 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3143 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2023 | 19811 | 0.050 |
Why?
|
Sperm Injections, Intracytoplasmic | 1 | 2023 | 159 | 0.050 |
Why?
|
Gravidity | 1 | 2021 | 51 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3248 | 0.050 |
Why?
|
Hospitalization | 3 | 2017 | 10208 | 0.050 |
Why?
|
Fertilization | 1 | 2023 | 196 | 0.050 |
Why?
|
Blood Cell Count | 1 | 2022 | 401 | 0.050 |
Why?
|
Lutein | 1 | 2022 | 125 | 0.050 |
Why?
|
Vitamin D | 1 | 2015 | 3197 | 0.050 |
Why?
|
Time Factors | 2 | 2020 | 40050 | 0.050 |
Why?
|
Phenotype | 1 | 2018 | 16301 | 0.050 |
Why?
|
Papillomaviridae | 2 | 2019 | 1117 | 0.050 |
Why?
|
Male | 9 | 2023 | 349022 | 0.050 |
Why?
|
Semen | 1 | 2023 | 316 | 0.050 |
Why?
|
Hysteroscopy | 1 | 2021 | 102 | 0.050 |
Why?
|
Community Health Centers | 1 | 2023 | 428 | 0.050 |
Why?
|
X-Rays | 1 | 2021 | 300 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2016 | 21694 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6310 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2022 | 791 | 0.040 |
Why?
|
Piperazines | 1 | 2010 | 2480 | 0.040 |
Why?
|
Platelet Count | 1 | 2022 | 780 | 0.040 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2019 | 124 | 0.040 |
Why?
|
Natural Killer T-Cells | 1 | 2022 | 315 | 0.040 |
Why?
|
Stillbirth | 1 | 2021 | 346 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 528 | 0.040 |
Why?
|
Uterine Perforation | 1 | 2018 | 7 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2022 | 615 | 0.040 |
Why?
|
Specimen Handling | 1 | 2023 | 692 | 0.040 |
Why?
|
Human papillomavirus 18 | 1 | 2019 | 127 | 0.040 |
Why?
|
Thyrotropin | 1 | 2022 | 849 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12328 | 0.040 |
Why?
|
Gold | 1 | 2022 | 484 | 0.040 |
Why?
|
Aneuploidy | 1 | 2021 | 533 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2022 | 779 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5272 | 0.040 |
Why?
|
Societies, Scientific | 1 | 2019 | 220 | 0.040 |
Why?
|
Pyrimidines | 1 | 2010 | 2918 | 0.040 |
Why?
|
Contraceptive Devices, Female | 1 | 2017 | 43 | 0.040 |
Why?
|
Medical Audit | 1 | 2019 | 466 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2022 | 4424 | 0.040 |
Why?
|
CpG Islands | 1 | 2021 | 1163 | 0.040 |
Why?
|
Vitamin A | 1 | 2020 | 613 | 0.040 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 261 | 0.040 |
Why?
|
Body Surface Area | 1 | 2017 | 198 | 0.040 |
Why?
|
APACHE | 1 | 2017 | 277 | 0.040 |
Why?
|
Ovarian Hyperstimulation Syndrome | 1 | 2017 | 53 | 0.040 |
Why?
|
Blotting, Western | 2 | 2015 | 5181 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2021 | 12985 | 0.030 |
Why?
|
Gonadotropins | 1 | 2017 | 241 | 0.030 |
Why?
|
Pregnancy, Multiple | 1 | 2017 | 217 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2020 | 689 | 0.030 |
Why?
|
RNA Interference | 2 | 2016 | 2899 | 0.030 |
Why?
|
Carboplatin | 1 | 2019 | 800 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2022 | 1783 | 0.030 |
Why?
|
Lost to Follow-Up | 1 | 2016 | 108 | 0.030 |
Why?
|
Capsid Proteins | 1 | 2019 | 479 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2084 | 0.030 |
Why?
|
Trauma Severity Indices | 1 | 2017 | 480 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2016 | 192 | 0.030 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2016 | 215 | 0.030 |
Why?
|
Ovulation Induction | 1 | 2017 | 274 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1029 | 0.030 |
Why?
|
Fetal Death | 1 | 2017 | 446 | 0.030 |
Why?
|
Lymphocytes | 1 | 2022 | 2612 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2022 | 2704 | 0.030 |
Why?
|
Registries | 2 | 2020 | 8039 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2019 | 760 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 21507 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2022 | 1925 | 0.030 |
Why?
|
New England | 1 | 2017 | 1021 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2021 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2008 | 11460 | 0.030 |
Why?
|
Caspase 3 | 1 | 2016 | 758 | 0.030 |
Why?
|
Antibodies | 1 | 2022 | 2450 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2022 | 4374 | 0.030 |
Why?
|
Oligonucleotides, Antisense | 1 | 2016 | 432 | 0.030 |
Why?
|
North America | 1 | 2017 | 1249 | 0.030 |
Why?
|
Live Birth | 1 | 2017 | 512 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2007 | 21863 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 2270 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3562 | 0.030 |
Why?
|
Monocytes | 1 | 2022 | 2583 | 0.030 |
Why?
|
Europe | 1 | 2019 | 3331 | 0.030 |
Why?
|
Ovary | 1 | 2017 | 982 | 0.030 |
Why?
|
bcl-X Protein | 1 | 2014 | 413 | 0.030 |
Why?
|
Antioxidants | 1 | 2020 | 1659 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2014 | 411 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2014 | 342 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2020 | 10455 | 0.030 |
Why?
|
Vitamins | 1 | 2020 | 1602 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2007 | 19220 | 0.030 |
Why?
|
DNA-Binding Proteins | 2 | 2021 | 9622 | 0.030 |
Why?
|
Tumor Burden | 1 | 2017 | 1904 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2016 | 2256 | 0.020 |
Why?
|
Specialization | 1 | 2016 | 776 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2948 | 0.020 |
Why?
|
Mesoderm | 1 | 2014 | 683 | 0.020 |
Why?
|
Genomics | 1 | 2007 | 5652 | 0.020 |
Why?
|
Gait | 1 | 2016 | 781 | 0.020 |
Why?
|
Nanoparticles | 1 | 2022 | 1906 | 0.020 |
Why?
|
Viral Load | 1 | 2019 | 3299 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2007 | 10142 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1654 | 0.020 |
Why?
|
Epithelium | 1 | 2014 | 1684 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2014 | 705 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2017 | 2897 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 12049 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2020 | 3087 | 0.020 |
Why?
|
Osteoblasts | 1 | 1975 | 1163 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 2017 | 1283 | 0.020 |
Why?
|
Transcription Factors | 2 | 2021 | 12120 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4182 | 0.020 |
Why?
|
Social Class | 1 | 2017 | 1974 | 0.020 |
Why?
|
Streptokinase | 1 | 2008 | 188 | 0.020 |
Why?
|
Peritoneal Neoplasms | 1 | 2014 | 663 | 0.020 |
Why?
|
United States | 3 | 2021 | 69573 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2017 | 6174 | 0.020 |
Why?
|
Pre-Eclampsia | 1 | 2017 | 1194 | 0.020 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1975 | 947 | 0.020 |
Why?
|
Genotype | 1 | 2022 | 12951 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8307 | 0.020 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2007 | 202 | 0.020 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2007 | 140 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3564 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2014 | 1522 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 20676 | 0.020 |
Why?
|
Enterotoxins | 1 | 2008 | 366 | 0.020 |
Why?
|
Isoenzymes | 1 | 2011 | 1720 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4743 | 0.020 |
Why?
|
Motor Activity | 1 | 2016 | 2719 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3603 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2017 | 3454 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2016 | 2901 | 0.020 |
Why?
|
Laparoscopy | 1 | 2017 | 2091 | 0.020 |
Why?
|
Candida albicans | 1 | 2008 | 392 | 0.020 |
Why?
|
Premature Birth | 1 | 2017 | 1702 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 2409 | 0.020 |
Why?
|
Base Sequence | 1 | 2016 | 12804 | 0.020 |
Why?
|
Benzamides | 1 | 2010 | 1374 | 0.020 |
Why?
|
Quality Improvement | 1 | 2019 | 3730 | 0.010 |
Why?
|
Inpatients | 1 | 2015 | 2478 | 0.010 |
Why?
|
Sepsis | 1 | 2017 | 2571 | 0.010 |
Why?
|
Patient Readmission | 1 | 2017 | 3106 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6516 | 0.010 |
Why?
|
Comorbidity | 1 | 2017 | 10362 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25470 | 0.010 |
Why?
|
Child | 3 | 2018 | 77033 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 1975 | 2521 | 0.010 |
Why?
|
Boston | 1 | 2015 | 9314 | 0.010 |
Why?
|
Spleen | 1 | 2007 | 2359 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2010 | 2507 | 0.010 |
Why?
|
Infant | 1 | 2023 | 34923 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9259 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8274 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2008 | 3193 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18349 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5830 | 0.010 |
Why?
|
Physicians | 1 | 2016 | 4539 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20055 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4400 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2007 | 5863 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23294 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1975 | 377 | 0.010 |
Why?
|
Gene Expression | 1 | 2007 | 7788 | 0.010 |
Why?
|
Cytokines | 1 | 2007 | 7298 | 0.010 |
Why?
|
Fluorouracil | 1 | 1975 | 1609 | 0.010 |
Why?
|
Child, Preschool | 1 | 2008 | 40802 | 0.000 |
Why?
|
Neoplasm Metastasis | 1 | 1975 | 4832 | 0.000 |
Why?
|
Radiography | 1 | 1975 | 6998 | 0.000 |
Why?
|